Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 18, 2006. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, rather than a comprehensive financial statement.
Key Financial Metrics
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. The only financial figure disclosed is the share price of GBP14.92 per share associated with a specific transaction.
Material Changes
No material changes to the company's financial position or operations are reported in this document. The filing details a specific increase in shareholdings by administrators of the SmithKline Beecham Bonus Investment Plan following the re-investment of dividends paid on April 6, 2006.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It strictly adheres to the requirements of Disclosure Rule 3.1.4R(1)(a) regarding the notification of the transaction involving Mr. R Bondy.
Key Facts for Investor Verification
- Transaction Date: April 13, 2006 (Notification date).
- Transaction Type: Increase in interest in Ordinary Shares via dividend re-investment.
- Share Price: GBP14.92 per share.
- Dividend Payment Date: April 6, 2006.
- Involved Party: Mr. R Bondy (Administrator of the SmithKline Beecham Bonus Investment Plan).